solute carrier family 7 member 7Genealiases: LAT3 · LPI · MOP-2 · Y+LAT1 · y+LAT-1
Q-omics provides the consensus-scored SLC7A7 profile across patient tissues and cancer cell-line models. SLC7A7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC7A7 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, SLC7A7 RNA expression shows 22,643 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where SLC7A7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC7A7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC7A7 survival associations across molecular data types. SLC7A7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC7A7 RNA expression–survival associations across cancer types. High SLC7A7 expression shows unfavorable associations in ACC, UVM, STAD and LGG, but favorable associations in SKCM and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC7A7 RNA expression.
This table summarizes SLC7A7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC7A7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC7A7 shows lower tumor expression in LUAD, LUSC and KICH and higher tumor expression in HNSC, STAD and BRCA. The HNSC box plot shows higher SLC7A7 RNA expression in tumor versus normal tissue (log2 FC = +1.236, t-test p < 0.001).
This table shows molecular features associated with SLC7A7 in patient tissues and cancer cell lines. In patient samples, SLC7A7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC7A7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
